Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study
Article first published online: 9 MAR 2006
Volume 97, Issue 4, pages 747–751, April 2006
How to Cite
NISHINO, Y., MASUE, T., MIWA, K., TAKAHASHI, Y., ISHIHARA, S. and DEGUCHI, T. (2006), Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU International, 97: 747–751. doi: 10.1111/j.1464-410X.2006.06030.x
- Issue published online: 9 MAR 2006
- Article first published online: 9 MAR 2006
- Accepted for publication 25 October 2005
- randomized crossover study;
- tamsulosin hydrochloride
To compare the efficacy of two α1-adrenoceptor antagonists, α1A-adrenoceptor-selective tamsulosin hydrochloride and α1D-adrenoceptor-selective naftopidil, in the treatment of lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH).
PATIENTS AND METHODS
Thirty-four patients (mean age 72.4 years, sd 4.3, range 66–79) with LUTS (International Prostate Symptom Score, IPSS >8) secondary to BPH were enrolled in a randomized crossover study. Seventeen patients were initially prescribed naftopidil 50 mg for 4 weeks, followed by tamsulosin 0.2 mg for 4 weeks (group A); another 17 were initially prescribed tamsulosin 0.2 mg, followed by naftopidil 50 mg (group B). Patients changed to the alternative treatment after a 1-week washout period. Efficacy criteria were improvement in LUTS (IPSS), quality of life (QoL), uroflowmetry, and pressure-flow study (PFS) values based on the treatment with each agent.
At baseline there were no significant differences between the groups in IPSS, QoL, uroflowmetry values or PFS values, except for the volume at maximum desire to void. After treatment with each agent, the IPSS and QoL were significantly improved and the reduction in bladder outlet obstruction confirmed by PFS. Naftopidil was significantly more effective than tamsulosin in relieving nocturia. The increases from baseline (before treatment) to the endpoint (after treatment with each agent) in the volume at first desire and maximum desire to void were significantly higher with naftopidil than with tamsulosin. Involuntary contractions disappeared in two patients with relief of nocturia with naftopidil, but not with tamsulosin. The decrease in other symptoms of the IPSS, QoL, increase in uroflowmetry values and changes in other PFS values were similar for both agents.
The two agents provided similar efficacy in the treatment of LUTS with BPH. However, naftopidil was better than tamsulosin for nocturia. The disappearance of involuntary contraction and the greater increase in first-desire volume with naftopidil may be associated with the relief of nocturia. The α1D-adrenoceptor antagonist is effective in alleviating both voiding and storage symptoms. The α1D-adrenoceptor antagonist may be more effective than the α1A-adrenoceptor antagonist in LUTS with BPH.